
|Articles|July 16, 2021
- Vol 38, Issue 7
Two Crises I Didn’t Train For
Author(s)Richard M. Berlin, MD
"I can still hear my patient shriek..."
Advertisement
POETRY OF THE TIMES
Telepsychiatry makes it easier for psychiatrists to treat patients by eliminating the need for either party to travel, with services provided from the safety and comfort of the psychiatrist’s home.
- a Telepsych website
I can still hear my patient shriek
when a black bear appeared on camera
behind me, circled the rose garden sundial,
and reared up to study one small human
shielded only by a sunroom screen,
three hundred feral pounds of muscle
and claw, almost as frightening
as a virus a tenth of a micron wide.
Dr Berlin has been writing a poem about his experience of being a doctor every month for the past 23 years in Psychiatric TimesTM in a column called “Poetry of the Times.” He is instructor in psychiatry, University of Massachusetts Medical School, Worcester, Massachusetts. ❒
Articles in this issue
over 5 years ago
What Is Resilience?over 5 years ago
Is Epstein-Barr Virus to Blame for Cognition in Schizophrenia?over 5 years ago
Faith Communities and the Well-Being of LGBTQ Youthover 5 years ago
Shining a Spotlight on Bright Light for Acute Bipolar Depressionover 5 years ago
Addressing Apathy in Dementiaover 5 years ago
The Rise in Synthetic Cannabinoids and Cathinonesover 5 years ago
Perfecting the TrifectaAdvertisement
Related to this article

In 2 pivotal phase 3 studies, all 5 readers hit sensitivity and specificity targets for florquinitau F 18 tau PET, including in patients with early symptomatic Alzheimer disease.

Clinicians weigh ketamine vs FDA-approved esketamine for TRD, with evolving guidance on dosing, safety monitoring, and long-term maintenance decisions.

Hormone shifts during menstruation, pregnancy, and menopause can trigger depression in susceptible women, highlighting connected brain pathways and guiding targeted, stabilizing treatments.

HLP003 achieved statistically significant and clinically meaningful results in the primary and key secondary endpoints starting as early as day 2.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Approves Igalmi for Agitation Associated With Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder
2
Rethinking Restrictive, Repetitive Behaviors in Autism
3
Positive Phase 3 Results: HLP003 as Adjunctive Treatment for Major Depressive Disorder
4
Morning Rounds: News From November 9-16
5




